Skip to content


Curemark has built a first-in-kind portfolio of products to treat neurological disorders that have previously been underserved by available options.

Our pipeline includes a pre-commercial asset for Autism Spectrum Disorder, a Phase III-ready product candidate for ADHD, two Phase II-ready assets in Parkinson’s and Schizophrenia.